December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Rami Manochakian: The FDA approves 1st line Osimertinib WITH chemotherapy for advanced EGFRm NSCLC.
Feb 17, 2024, 15:57

Rami Manochakian: The FDA approves 1st line Osimertinib WITH chemotherapy for advanced EGFRm NSCLC.

Rami Manochakian, Thoracic Oncologist and Hematology-Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter:

“Hot off the press.

The FDA approves 1st line Osimertinib WITH chemotherapy for advanced EGFRm non-small cell Lung Cancer.
Approval based on FLAURA2 trial which showed PFS compared to Osimertinib alone.

HR: 0.62
mPFS: 25.5 vs 16.7 months.”

Rami Manochakian: The FDA approves 1st line Osimertinib WITH chemotherapy for advanced EGFRm NSCLC.

View additional information.
Source: Rami Manochakian/X